Dave joined Samsara in the fall of 2021. Prior to Samsara, he worked within the Global BD organization at GSK focusing on search, evaluation and due diligence of immunology-focused opportunities for two years. Prior to his work within Global BD, Dave joined the Discovery Partnerships with Academia (DPAc) Research Unit at GSK, where he worked extensively with multiple US/EU academic institutions to identify and progress early-stage innovation utilizing the capabilities of pharma within a collaborative, milestone-based framework. Prior to GSK, he was at Portola Pharmaceuticals, working on inflammatory disease and oncology drug discovery/development. From 1999-2010 he worked at DNAX Research in Palo Alto where led research, drug discovery and early clinical development of small molecule efforts focused on the cell cycle, DNA damage/repair and biopharm targets in the immuno-oncology space. Dave received his B.Sc. (Hons) in Biochemistry from The University of Manchester Institute of Science and Technology (UMIST) and a Ph.D. in Molecular Oncology from The Imperial Cancer Research Fund (ICRF).